OncoSec Announces Publication In Nature Gene Therapy Demonstrating Efficacy Of IL-12 Intratumoral Gene Electrotransfer Mar 12, 2018 8:00am EDT
OncoSec Medical Incorporated Announces Closing of $23.0 Million Public Offering of Common Stock Feb 06, 2018 8:30am EST
OncoSec Medical Incorporated Prices $20.0 Million Public Offering of Common Stock Feb 01, 2018 9:21am EST
OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock Jan 31, 2018 4:01pm EST
OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study Jan 18, 2018 9:15am EST
OncoSec Appoints Veteran Biopharma Executive Gregory T. Mayes To Board Of Directors Jan 16, 2018 8:00am EST
OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab Dec 14, 2017 8:00am EST
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer Dec 05, 2017 8:00am EST
OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform Nov 28, 2017 8:00am EST
